George Frangeskides, Exec-Chair at Alba Mineral Resources, discusses grades at the Clogau Gold Mine. Watch the full video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPlethora Solutions Holdings Plc Share News (PLE)

  • There is currently no data for PLE

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Plethora Solutions Continues Progress Towards Launch Of Fortacin

Mon, 10th Nov 2014 09:50

LONDON (Alliance News) - Plethora Solutions Holdings PLC Monday said it has received the EUR5 million upfront payment from Recordati after the companies recently signed a licensing deal for Plethora's premature ejacuation treatment, and it's still on track for a commercial launch in Europe in the third quarter of next year.

Plethora shares jumped September 16 after it signed the licensing deal with pharmaceutical company Recordati for the commercialisation of premature ejaculation treatment PSD502, now trademarked as Fortacin. Recordati has the rights to commercialise the topical spray in the EU, Russia, the Commonwealth of Independent States, Turkey and some countries in North Africa.

There was a risk that Plethora would have to refund part of the upfront payment and have the deal terminated if certain conditions weren't met, including a satisfactory feasibility report.

"The company is pleased to announce that following delivery by the company to Recordati of a satisfactory feasibility report, Recordati has confirmed that no refund is payable by the company and that Recordati has no intention of terminating the agreement," Plethora said in a statement.

Fortacin was approved by the European Commission in November 2013, but the company is now looking for approval for a variation of the marketing approval for a new six dose canister.

The company also said its manufacturing partner Pharmaserve North West Ltd expects to complete production of the first 'good manufacturing practices' batch of the six dose canisters of Fortacin in a few days time. The manufacturer also plans to start the second batch next week, and therefore Plethora said it remains on track to complete the batch stability and validation studies required for EU variation approval for the six dose canister by the end of 2014.

It therefore still expects the European Medical Agency's Committee for Medicinal Products for Human Use to approve Fortacin during the third quarter of 2015, and this marketing authorisation will trigger the immediate commercial launch of the product in the European Union by Recordati.

Plethora shares were up 0.1% at 141.10 pence Monday morning.

By Steve McGrath; stevemcgrath@alliancenews.com; @stevemcgrath1

Copyright 2014 Alliance News Limited. All Rights Reserved.

More News
23 Dec 2015 09:39

Plethora Agrees GBP1.0 Million Loan Facility With Buyer Regent Pacific

Read more
22 Dec 2015 12:02

Port Erin Biopharma Continues To Look For Investments, Swings To Loss

Read more
15 Dec 2015 13:57

Plethora Solutions recommends GBP96m Regent Pacific offer

(ShareCast News) - Plethora Solutions, which is developing a treatment for premature ejaculation, has agreed on a takeover by Hong Kong-listed Regent Pacific that values the AIM company at roughly £96m or 11.65p per share. At Regent Pacific's closing price on Monday, this valued Plethora at a level

Read more
15 Dec 2015 13:47

Regent Pacific To Acquire Plethora Solutions For GBP114.3 Million

Read more
4 Nov 2015 12:19

LONDON MARKET MIDDAY: US Stocks Seen Up Ahead Of Data, Earnings

Read more
4 Nov 2015 10:32

Plethora Solutions Shares Soar, Agrees Regent Pacific Takeover Terms

Read more
4 Nov 2015 10:31

WINNERS & LOSERS SUMMARY: Housebuilders And Estate Agents Torn Down

Read more
28 Aug 2015 15:36

Plethora Interim Loss Narrows As Product Development Continues

Read more
5 Jun 2015 11:30

Plethora Ends Deal With Sharwood, Substitutes Deal With Regent Pacific

Read more
12 May 2015 08:43

Plethora Solutions Appoints New CFO, Non-Executive Director

Read more
30 Mar 2015 12:15

Port Erin Biopharma Swings To First Half Loss As Gains Do Not Recur

Read more
11 Nov 2014 10:48

Plethora Says Fortacin Prescription Sales May Hit USD1 Billion A Year

Read more
7 Oct 2014 08:50

Plethora Solutions' Treatment To Be Marketed As Fortacin In EU

Read more
29 Sep 2014 13:40

Plethora Says Forest Nominees To Convert Loan Notes Into Shares (ALLISS)

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.